Dubai-based investment firm All Blue Capital has put a $773 million offer on the table for Zymeworks, the Vancouver-based biotech with operations in Seattle. According to a regulatory filing, the non-binding proposal prices shares at $10.50 each—more than double the $4.88 closing price the day prior. The stock gained more than 30% in after-hours trading after Reuters first reported the bid.
This is a contested deal in a battered biotech. The board will have to weigh a generous premium against a company that has been through a rough stretch.
- All Blue already holds close to 5.5% of Zymeworks shares.
- Zymeworks replaced its CEO in January with Kenneth Galbraith.
- Galbraith announced plans to cut about a quarter of the workforce.
- The company raised $100 million in a January public offering, pricing shares near $8.
- Shares traded above $50 early last year, highlighting the slide.
- All Blue's letter accuses leadership of "severe value erosion" and "no clear strategy."
Why an activist buyer is interested
All Blue's letter to the board is unusually blunt, accusing current leadership of "severe value erosion" and an unfocused strategy. The firm already owns about 5.5% of the company, which gives it standing to push for change even before any deal closes. That earlier stake also means All Blue stands to gain on both the premium and any post-deal recovery if shareholders approve.
What Zymeworks is working on
Zymeworks develops bispecific antibodies that recognize two different molecular targets simultaneously, along with other treatment platforms. Its lead candidate is in late-stage clinical trials—typically where biotech assets command the highest valuations but also face the steepest regulatory hurdles.
Our analysis
For biotech followers, this is a textbook case of an activist investor testing a depressed stock. The premium is real—more than double the prior close—and the public letter signals All Blue is willing to be loud. The trade-off for shareholders is whether a higher offer materializes, since public scolding often attracts competing bids. The risk: no one else shows up and shareholders vote the offer through simply because the stock has been weak for a year.
| Factor | What it means here |
|---|---|
| Premium | 115% above prior close—hard to ignore |
| Timing | Stock near 52-week low, not near the peak |
| Pipeline stage | Late-phase trials reduce binary risk |
| Activist stance | Public letter suggests no friendly deal |
For the sector, the watch item is whether this is a one-off or the start of a wave. Biotech valuations have been hammered since the 2021 peak, and a successful take-private at a generous premium could invite similar bids at smaller names with late-stage pipelines. Watch for other activist letters at biotechs trading below cash.
Who should care
Long-term Zymeworks shareholders:** The offer is above your cost basis if you bought in the last year. Take a hard look at the pipeline's probability-weighted value versus $10.50.
Short-term traders:** The 30% jump may be overdone if the board rejects or negotiates. The spread could compress quickly.
Employees:** Galbraith's restructuring plan is already in motion. A buyout could accelerate cuts or change the R&D focus entirely.
Sector watchers:** This deal, if it closes, sets a benchmark for how cheap small-cap biotech has become.
Bottom line
A loud $773 million offer is on the table for a biotech that had lost most of its value over the prior year. The premium is real, the criticism is public, and the next move belongs to the board.
Key takeaways
- All Blue Capital has offered a substantial premium to take the biotech private.
- The public criticism signals a contested process, not a friendly one.
- Watch for competing bids; public letters often attract them.
- Late-stage pipeline assets may draw similar interest from activists.
Frequently asked questions
How much is All Blue Capital offering for Zymeworks?
A non-binding offer of $773 million in cash, at $10.50 per share, according to a regulatory filing.
Why does All Blue already own Zymeworks shares?
All Blue is an existing investor and currently holds close to 5.5% of the company's stock.
What does Zymeworks do?
Zymeworks develops bispecific antibodies that target two different molecular targets at once, along with other treatment platforms.
What is Zymeworks' lead product?
Its lead candidate is in late-stage clinical trials, though the specific candidate was not named in the filing.
What happens next?
The board must review the proposal. Non-binding offers can be rejected, negotiated, or serve as a starting point for talks with other potential buyers.